Pietrzak I, Baczyk K, Kubiak W
Department of Nephrology, University School of Medical Sciences, Poznan, Poland.
Miner Electrolyte Metab. 1996;22(1-3):102-5.
The influence of r-HuEPO on the activity of erythrocyte transketolase (ETKA), glutathione reductase (GSH) and glutamic-pyruvic transaminase (EGPT) was determined by spectrophotometry. 150 IU/kg BW/week of r-HuEPO was given i.v. during 2 months to 12 predialyzed uremics (PDU). Twenty healthy volunteers (HV) served as controls. GSH and EGPT activity were expressed as a coefficient. ETKA in HV = 2.39 +/- 0.10 and PDU = 1.53 +/- 0.10 mumol/ml/min differed significantly (p < 0.001). GSH in HV = 1.20 +/- 0.09 and PDU = 1.25 +/- 0.07, EGPT in HV = 1.20 +/- 0.10 and PDU = 1.38 +/- 0.11 differed significantly (p < 0.01 and p < 0.001, respectively). After 2 months of r-HuEPO treatment, ETKA, GSH and EGPT rose significantly (p < 0.01). Thus, r-HuEPO increases the activity of enzymes related with the content of vitamins B1, B2 and B6 in uremics.
采用分光光度法测定重组人促红细胞生成素（r-HuEPO）对红细胞转酮醇酶（ETKA）、谷胱甘肽还原酶（GSH）和谷丙转氨酶（EGPT）活性的影响。给12例透析前尿毒症患者（PDU）静脉注射r-HuEPO，剂量为150 IU/kg体重/周，持续2个月。20名健康志愿者（HV）作为对照。GSH和EGPT活性以系数表示。HV组ETKA为2.39±0.10，PDU组为1.53±0.10 μmol/ml/min，差异有统计学意义（p<0.001）。HV组GSH为1.20±0.09，PDU组为1.25±0.07；HV组EGPT为1.20±0.10，PDU组为1.38±0.11，差异有统计学意义（分别为p<0.01和p<0.001）。r-HuEPO治疗2个月后，ETKA、GSH和EGPT显著升高（p<0.01）。因此，r-HuEPO可提高尿毒症患者体内与维生素B1、B2和B6含量相关的酶的活性。
